Resverlogix Corp.(RVX-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0900
Day High0.0950
Open:0.0950
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Resverlogix Announces One-Year Extension of Debenture
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Resverlogix Corp. Announces Issuance of MCTO by ASC
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
Resverlogix Appoints Bradley Glass to Board of Directors
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders

Profile

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.